AVR/I/SSAPDB: a comprehensive & specialised knowledgebase of antimicrobial peptides to combat VRSA, VISA, and VSSA

Rajat Kumar Mondal1, Debayan Karmakar1, Oshin Pal1

  • 1Biochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, (IIIT-A), Devghat, Jhalwa, Prayagraj, Uttar Pradesh, 211012, India.

Insights

A new database, AVR/I/SSAPDB, catalogs 491 antimicrobial peptides targeting Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus (VISA), and Vancomycin-susceptible S. aureus (VSSA). This resource aids in developing new peptide-based therapeutics against these dangerous bacteria.

Area of Science:

  • Microbiology
  • Biotechnology
  • Drug Discovery

Background:

  • Multi-drug resistant bacteria, particularly Staphylococcus aureus strains like VRSA, VISA, and VSSA, present a significant global health challenge.
  • The emergence of resistance necessitates the development of novel antimicrobial agents.

Purpose of the Study:

  • To introduce the Anti-Vancomycin-Resistant/Intermediate/Susceptible Staphylococcus aureus Peptide Database (AVR/I/SSAPDB).
  • To provide a specialized, manually curated knowledgebase of antimicrobial peptides (AMPs) effective against VRSA, VISA, and VSSA.

Main Methods:

  • Data was collected from PubMed and curated manually.
  • The database includes 491 experimentally validated AMPs with detailed annotations.
  • Cross-references to external databases such as PubMed, UniProt, PDB, and DrugBank are provided.

Main Results:

  • The AVR/I/SSAPDB contains comprehensive information on AMPs targeting specific Staphylococcus aureus strains.
  • It offers a user-friendly interface with various search functionalities for researchers.

Conclusions:

  • The AVR/I/SSAPDB serves as a valuable resource for the scientific community.
  • It aims to facilitate the development of targeted peptide-based therapeutics to combat resistant Staphylococcus aureus strains and address public health concerns.